CURRENT ADVANCES IN LIPOPROTEIN(A) MANAGEMENT: CLINICAL SIGNIFICANCE AND EMERGING THERAPIES
Abstract
Background: Lipoprotein(a) [Lp(a)] is an independent, genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Despite its clinical importance, Lp(a) remains largely unaffected by traditional lipid-lowering therapies, contributing to significant residual cardiovascular risk.
Aim: This review aims to synthesize current knowledge regarding the clinical significance of elevated lipoprotein(a) levels and to explore the landscape of emerging therapeutic strategies designed to specifically address this challenging cardiovascular risk factor.
Materials and Methods: An extensive synthesis of the current literature, prioritizing comprehensive review articles and meta-analyses published within the last five years, was conducted using multiple electronic databases (PubMed, Scopus, Google Scholar).
Results: Epidemiological data indicate that 20–30% of the global population has elevated Lp(a) levels (>30–50 mg/dL). While lifestyle and statins show negligible effects on Lp(a) concentration, novel nucleic acid-based therapies - specifically antisense oligonucleotides (pelacarsen) and small interfering RNAs (olpasiran, lepodisiran, zerlasiran) have demonstrated the ability to reduce Lp(a) levels by 70% to over 95%. Furthermore, oral small-molecule inhibitors like muvalaplin offer promising alternatives by disrupting the assembly of the Lp(a) particle.
Conclusion: The emergence of targeted RNA-based and small-molecule therapies represents a paradigm shift in cardiovascular prevention. As phase 3 clinical trials progress, these interventions may provide the first definitive means of mitigating the residual risk associated with elevated Lp(a).
References
Ballena-Caicedo, J., Zuzunaga-Montoya, F. E., Loayza-Castro, J. A., Vásquez-Romero, L. E. M., Tapia‐Limonchi, R., Carrillo, C. I. G. D., & Vera-Ponce, V. J. (2025). Global prevalence of dyslipidemias in the general adult population: a systematic review and meta-analysis [Review of Global prevalence of dyslipidemias in the general adult population: a systematic review and meta-analysis]. Journal of Health Population and Nutrition, 44(1). BioMed Central. https://doi.org/10.1186/s41043-025-01054-3
Bekbossynova, M., Saliev, T., Ivanova-Razumova, T., Andossova, S., Kali, A., & Myrzakhmetova, G. (2025). Beyond Cholesterol: Emerging Risk Factors in Atherosclerosis [Review of Beyond Cholesterol: Emerging Risk Factors in Atherosclerosis]. Journal of Clinical Medicine, 14(7), 2352. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/jcm14072352
Corte, V. D., Todaro, F., Cataldi, M., & Tuttolomondo, A. (2023). Atherosclerosis and Its Related Laboratory Biomarkers [Review of Atherosclerosis and Its Related Laboratory Biomarkers]. International Journal of Molecular Sciences, 24(21), 15546. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/ijms242115546
Cui, D., Yu, X., Guan, Q., Shen, Y., Liao, J., Liu, Y., & Su, Z. (2025). Cholesterol metabolism: molecular mechanisms, biological functions, diseases, and therapeutic targets. Molecular Biomedicine, 6(1). https://doi.org/10.1186/s43556-025-00321-3
Fujino, M., Giovanni, G. D., & Nicholls, S. J. (2024). New Approaches to Lipoproteins for the Prevention of Cardiovascular Events [Review of New Approaches to Lipoproteins for the Prevention of Cardiovascular Events]. Journal of Atherosclerosis and Thrombosis, 32(3), 265. Japan Atherosclerosis Society. https://doi.org/10.5551/jat.rv22031
Gary, S., Chiou, T., & Wilkinson, M. J. (2023). Is Lipoprotein(a) Clinically Actionable with Today’s Evidence? The Answer is Yes [Review of Is Lipoprotein(a) Clinically Actionable with Today’s Evidence? The Answer is Yes]. Current Cardiology Reports, 25(10), 1175. Springer Science+Business Media. https://doi.org/10.1007/s11886-023-01937-z
Greco, A., Finocchiaro, S., Spagnolo, M., Faro, D. C., Mauro, M. S., Raffo, C., Sangiorgio, G., Imbesi, A., Laudani, C., Mazzone, P. M., Ammirabile, N., Giacoppo, D., Landolina, D., & Capodanno, D. (2025). Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects [Review of Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects]. Circulation, 151(6), 400. Lippincott Williams & Wilkins. https://doi.org/10.1161/circulationaha.124.069210
Jang, A. Y., Han, S. H., Sohn, I. S., Oh, P. C., & Koh, K. K. (2020). Lipoprotein(a) and Cardiovascular Diseases ― Revisited ― [Review of Lipoprotein(a) and Cardiovascular Diseases ― Revisited ―]. Circulation Journal, 84(6), 867. Japanese Circulation Society. https://doi.org/10.1253/circj.cj-20-0051
Kalwick, M., & Roth, M. (2025). A Comprehensive Review of the Genetics of Dyslipidemias and Risk of Atherosclerotic Cardiovascular Disease [Review of A Comprehensive Review of the Genetics of Dyslipidemias and Risk of Atherosclerotic Cardiovascular Disease]. Nutrients, 17(4), 659. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/nu17040659
Kim, K., Ginsberg, H. N., & Choi, S. H. (2022). New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins [Review of New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins]. Diabetes & Metabolism Journal, 46(4), 517. Korean Diabetes Association. https://doi.org/10.4093/dmj.2022.0198
Koren, M. J., Moriarty, P. M., Baum, S. J., Neutel, J., Hernandez‐Illas, M., Weintraub, H., Florio, M., Kassahun, H., Melquist, S., Varrieur, T., Haldar, S. M., Sohn, W., Wang, H., Elliott‐Davey, M., Rock, B. M., Pei, T., Homann, O., Hellawell, J., & Watts, G. F. (2022). Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nature Medicine, 28(1), 96. https://doi.org/10.1038/s41591-021-01634-w
Koschinsky, M. L., Bajaj, A., Boffa, M. B., Dixon, D. L., Ferdinand, K. C., Gidding, S. S., Gill, E. A., Jacobson, T. A., Michos, E. D., Safarova, M., Soffer, D., Taub, P. R., Wilkinson, M. J., Wilson, D. P., & Ballantyne, C. M. (2024). A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice [Review of A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice]. Journal of Clinical Lipidology, 18(3). Elsevier BV. https://doi.org/10.1016/j.jacl.2024.03.001
Koutsogianni, A. D., Adamidis, P. S., Barkas, F., Liberopoulos, E., Su, T., Yamashita, S., Liamis, G., & Rizzo, M. (2022). Familial Hypercholesterolemia and Lipoprotein(a): A Gordian Knot in Cardiovascular Prevention [Review of Familial Hypercholesterolemia and Lipoprotein(a): A Gordian Knot in Cardiovascular Prevention]. Metabolites, 12(11), 1065. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/metabo12111065
Kozárová, M., Lacková, A., Kozelová, Z., & Tomčo, L. (2023). Lipoprotein (a): A Novel Cardiovascular Risk Factor. Balkan Medical Journal, 40(4), 234. https://doi.org/10.4274/balkanmedj.galenos.2023.2023-4-8
Kronenberg, F. (2024). Lipoprotein(a): from Causality to Treatment [Review of Lipoprotein(a): from Causality to Treatment]. Current Atherosclerosis Reports, 26(3), 75. Springer Science+Business Media. https://doi.org/10.1007/s11883-024-01187-6
Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M. L., Lambert, G., Mach, F., McNeal, C. J., Moriarty, P. M., Natarajan, P., Nordestgaard, B. G., Parhofer, K. G., Virani, S. S., Eckardstein, A. von, Watts, G. F., Stock, J. K., … Catapano, A. L. (2022). Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal, 43(39), 3925. https://doi.org/10.1093/eurheartj/ehac361
Krychtiuk, K. A., Rader, D. J., & Granger, C. B. (2022). RNA-targeted therapeutics in cardiovascular disease: the time is now. European Heart Journal - Cardiovascular Pharmacotherapy, 9(1), 94. https://doi.org/10.1093/ehjcvp/pvac052
Lee, S. (2021). Role of Genetics in Preventive Cardiology: Focused on Dyslipidemia [Review of Role of Genetics in Preventive Cardiology: Focused on Dyslipidemia]. Korean Circulation Journal, 51(11), 899. Korean Society of Circulation. https://doi.org/10.4070/kcj.2021.0239
Ma, Z., Zhong, J., Tu, W., Li, S., & Chen, J. (2024). The functions of apolipoproteins and lipoproteins in health and disease [Review of The functions of apolipoproteins and lipoproteins in health and disease]. Molecular Biomedicine, 5(1). Springer Nature. https://doi.org/10.1186/s43556-024-00218-7
Mach, F., Koskinas, K. C., Lennep, J. E. R. van, Tokgözoğlu, L., Badimón, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., Backer, G. D., Delgado, V., Fabin, N., Ference, B. A., Graham, I., Landmesser, U., Mihaylova, B., Nordestgaard, B. G., Richter, D., Sabatine, M. S., … Visser, L. (2025). 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal, 46(42), 4359. https://doi.org/10.1093/eurheartj/ehaf190
Nicholls, S. J. (2024). Therapeutic Potential of Lipoprotein(a) Inhibitors [Review of Therapeutic Potential of Lipoprotein(a) Inhibitors]. Drugs, 84(6), 637. Adis, Springer Healthcare. https://doi.org/10.1007/s40265-024-02046-z
Nissen, S. E., Linnebjerg, H., Shen, X., Wolski, K., Ma, X., Lim, S., Michael, L. F., Ruotolo, G., Gribble, G., Návar, A. M., & Nicholls, S. J. (2023). Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a). JAMA, 330(21), 2075. https://doi.org/10.1001/jama.2023.21835
Nissen, S. E., Wolski, K., Balog, C., Swerdlow, D. I., Scrimgeour, A., Rambaran, C., Wilson, R., Boyce, M., Ray, K. K., Cho, L., Watts, G. F., Koren, M. J., Turner, T., Stroes, E. S. G., Melgaard, C., & Campion, G. (2022). Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels. JAMA, 327(17), 1679. https://doi.org/10.1001/jama.2022.5050
Nissen, S. E., Wolski, K., Watts, G. F., Koren, M. J., Fok, H., Nicholls, S. J., Rider, D. A., Cho, L., Romano, S. J., Melgaard, C., & Rambaran, C. (2024). Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a). JAMA, 331(18), 1534. https://doi.org/10.1001/jama.2024.4504
Noothi, S. K., Ahmed, M. R., & Agrawal, D. K. (2023). Residual risks and evolving atherosclerotic plaques [Review of Residual risks and evolving atherosclerotic plaques]. Molecular and Cellular Biochemistry, 478(12), 2629. Springer Science+Business Media. https://doi.org/10.1007/s11010-023-04689-0
Nurmohamed, N. S., Kraaijenhof, J. M., & Stroes, E. S. G. (2022). Lp(a): a New Pathway to Target? [Review of Lp(a): a New Pathway to Target?]. Current Atherosclerosis Reports, 24(11), 831. Springer Science+Business Media. https://doi.org/10.1007/s11883-022-01060-4
O’Donoghue, M. L., Rosenson, R. S., Gencer, B., López, J. A. G., Lepor, N. E., Baum, S. J., Stout, E., Gaudet, D., Knüsel, B., Kuder, J., Ran, X., Murphy, S. A., Wang, H., Wu, Y., Kassahun, H., & Sabatine, M. S. (2022). Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. New England Journal of Medicine, 387(20), 1855. https://doi.org/10.1056/nejmoa2211023
Qin, T., Ma, T., Huang, K., Lu, S., Zhong, J., & Li, J. (2024). Lipoprotein (a)-Related Inflammatory Imbalance: A Novel Horizon for the Development of Atherosclerosis [Review of Lipoprotein (a)-Related Inflammatory Imbalance: A Novel Horizon for the Development of Atherosclerosis]. Current Atherosclerosis Reports, 26(8), 383. Springer Science+Business Media. https://doi.org/10.1007/s11883-024-01215-5
Reyes-soffer, G., Ginsberg, H. N., Berglund, L., Duell, P. B., Heffron, S. P., Kamstrup, P. R., Lloyd-Jones, D. M., Marcovina, S. M., Yeang, C., Koschinsky, M. L., Disease, on behalf of the A. H. A. C. on A., Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular, Reyes-soffer, G., Ginsberg, H. N., Berglund, L., Duell, P. B., Heffron, S. P., Kamstrup, P. R., Lloyd-Jones, D. M., Marcovina, S. M., … Disease, on behalf of the A. H. A. C. on A., Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular. (2021). Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arteriosclerosis Thrombosis and Vascular Biology, 42(1). https://doi.org/10.1161/atv.0000000000000147
Saniewski, T., Zimodro, J. M., Procyk, G., Wasilewska, O., Mroczyk, B., Lis, M., Banach, M., & Gąsecka, A. (2025). Incorporating lipoprotein (a) into patient care: Polish landscape in light of national recommendations and the updated ESC/EAS guidelines. Archives of Medical Science. https://doi.org/10.5114/aoms/212635
Sosnowska, B., Surma, S., & Banach, M. (2022). Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy [Review of Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy]. Pharmaceuticals, 15(12), 1573. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/ph15121573
Šuran, D., Vošner, H. B., Završnik, J., Kokol, P., Sinkovič, A., Kanič, V., Kokol, M., Naji, F., & Završnik, T. (2022). Lipoprotein(a) in Cardiovascular Diseases: Insight From a Bibliometric Study [Review of Lipoprotein(a) in Cardiovascular Diseases: Insight From a Bibliometric Study]. Frontiers in Public Health, 10. Frontiers Media. https://doi.org/10.3389/fpubh.2022.923797
Szarek, M., Bittner, V., Aylward, P. E., Baccara‐Dinet, M. T., Bhatt, D. L., Díaz, R., Fras, Z., Goodman, S. G., Halvorsen, S., Harrington, R. A., Jukema, J. W., Moriarty, P. M., Pordy, R., Ray, K. K., Sinnaeve, P., Tsimikas, S., Vogel, R. A., White, H. D., Zahger, D., … Schwartz, G. G. (2020). Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. European Heart Journal, 41(44), 4245. https://doi.org/10.1093/eurheartj/ehaa649
Thau, H., Neuber, S., Emmert, M. Y., & Nazari‐Shafti, T. Z. (2024). Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease? Cardiology and Therapy, 13(1), 39. https://doi.org/10.1007/s40119-024-00353-w
Tselepis, A. D. (2023). Treatment of Lp(a): Is It the Future or Are We Ready Today? [Review of Treatment of Lp(a): Is It the Future or Are We Ready Today?]. Current Atherosclerosis Reports, 25(10), 679. Springer Science+Business Media. https://doi.org/10.1007/s11883-023-01141-y
Tsimikas, S. (2017). A Test in Context: Lipoprotein(a) [Review of A Test in Context: Lipoprotein(a)]. Journal of the American College of Cardiology, 69(6), 692. Elsevier BV. https://doi.org/10.1016/j.jacc.2016.11.042
Tsimikas, S., Karwatowska‐Prokopczuk, E., Gouni‐Berthold, I., Tardif, J., Baum, S. J., Steinhagen-Thiessen, E., Shapiro, M. D., Stroes, E. S. G., Moriarty, P. M., Nordestgaard, B. G., Xia, S., Guerriero, J., Viney, N. J., O’Dea, L., & Witztum, J. L. (2020). Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. New England Journal of Medicine, 382(3), 244. https://doi.org/10.1056/nejmoa1905239
Wang, X., Yu, W., Jiang, G., Li, H., Li, S., Xie, L., Bai, X., Cui, P., Chen, Q., Lou, Y., Zou, L., Li, S., Zhou, Z., Zhang, C., Sun, P., & Mao, M. (2024). Global Epidemiology of Gallstones in the 21st Century: A Systematic Review and Meta-Analysis [Review of Global Epidemiology of Gallstones in the 21st Century: A Systematic Review and Meta-Analysis]. Clinical Gastroenterology and Hepatology, 22(8), 1586. Elsevier BV. https://doi.org/10.1016/j.cgh.2024.01.051
Wierzbowska, N., Olejnik-Wojciechowska, J., Dąbrowska, A., & Żurawska, K. (2024). Pharmacological methods to lower lipoprotein(a) levels. Medical Research Journal, 9(1), 96. https://doi.org/10.5603/mrj.99088
Yeang, C., Karwatowska‐Prokopczuk, E., Su, F., Dinh, B., Xia, S., Witztum, J. L., & Tsimikas, S. (2022). Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology, 79(11), 1035. https://doi.org/10.1016/j.jacc.2021.12.032
Zubirán, R., Neufeld, E. B., Dasseux, A., Remaley, A. T., & Sorokin, A. V. (2024). Recent Advances in Targeted Management of Inflammation In Atherosclerosis: A Narrative Review [Review of Recent Advances in Targeted Management of Inflammation In Atherosclerosis: A Narrative Review]. Cardiology and Therapy, 13(3), 465. Adis, Springer Healthcare. https://doi.org/10.1007/s40119-024-00376-3
Copyright (c) 2026 Szymon Zysiak, Rafał Bednarczyk, Natalia Bednarczyk, Agnieszka Kurek, Natalia Krajewska, Aleksandra Lejman, Aleksandra Mazurkiewicz, Hubert Sidor, Monika Wołosik, Radosław Krzysztof Binkowski
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
